Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

BACKGROUND: Trastuzumab emtansine (T-DM1) is a second-line standard therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Evidence regarding post–T-DM1 treatments is currently lacking. We evaluated the effectiveness of post–T-DM1 drug therapy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Takahiro, Yoshinami, Tetsuhiro, Yasojima, Hiroyuki, Kittaka, Nobuyoshi, Takahashi, Masato, Ohtani, Shoichiro, Kim, Seung Jin, Kurakami, Hiroyuki, Yamamoto, Naoko, Yamada, Tomomi, Takata, Takehiko, Masuda, Norikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268506/
https://www.ncbi.nlm.nih.gov/pubmed/34238257
http://dx.doi.org/10.1186/s12885-021-08504-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268506/
https://www.ncbi.nlm.nih.gov/pubmed/34238257
http://dx.doi.org/10.1186/s12885-021-08504-1

Ejemplares similares